drugset
drugset / Trial / NCT05133882

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

NCT05133882 ↗

Phase 1/2 Recruiting 133 enrolled Sunshine Lake Pharma Co., Ltd.
Non-randomizedSequentialSingle-blindTreatment

Summary

This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML

Timeline

Start
2022-10-31
Primary completion
2027-12-31
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Clifutinib Unknown 30 mg Oral
Subject Clifutinib Unknown 40 mg Oral
Subject Clifutinib Unknown 60 mg Oral

Indications

acute myeloid leukemia